Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.
Priyanka SharmaVandana G AbramsonAnne O'DeaLauren NyeIngrid MayerHarsh B PathakMarc HoffmannShane R SteckleinManana EliaSharon LewisJecinta ScottJilliann A De JongYen Y WangRachel YoderKelsey SchwensenKarissa FinkeJaimie HeldstabStephanie LaFaverStephen K WilliamsonMilind A PhadnisGregory A ReedBruce F KimlerQamar J KhanAndrew K GodwinPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
The alpelisib plus nab-paclitaxel combination was well tolerated and shows encouraging efficacy, especially in patients with PIK3CA-mutated tumor/ctDNA. The impact of metabolic status on response to this combination merits further investigation.